Treatments for Choroidal Neovascularization (CNV)
$ Current Anti-VEGF treatments
¬ Bevacizumab (Avastin)
2 Humanized full length monoclonal antibody
2 AMD
¬ Ranibizumab (Lucentis)
2 Humanized monoclonal antibody fragment 
2 AMD, DME, DR, RVO
¬ Aflibercept (Eylea)
2 Fusion protein 
2 AMD, DME, DR
¬ brolucizumab-dbll (Beovu)
2 Humanized single-chain antibody fragment
2 Up to 3 months dosing intervals, most are 4-6 weeks
–
50% remained 3 months after 1 year 
¬ Pegaptanib (Macugen)
2 RNA aptamer
2 AMD
